To further evaluate the safety of dihydrocapsiate (4-hydroxy-3-methoxybenzyl 8-methylnonanoate, CAS No. 205687-03-2), a 26-week gavage toxicity study was conducted in Sprague-Dawley rats (20/sex/group). Test animals received either dihydrocapsiate, 100, 300, or 1000 mg/kg/day, or vehicle (medium-chain triglyceride) by gavage and were observed for antemortem and postmortem signs of toxicity including changes in clinical signs, body weights, food consumption, water intake, ophthalmology, clinical pathology (clinical chemistry, hematology, urinalysis), tissue findings (macroscopic and microscopic examination), as well as organ weights. After the end of the dosing period, reversibility was assessed (10/sex/group for the control and 1000 mg/kg groups) following a 4-week recovery period. There were no adverse or toxicological changes observed in clinical signs, body weight, food consumption, water intake, ophthalmology, urinalysis, hematology, blood chemistry, organ weights, or histopathology. It was concluded that the no observable adverse effect level (NOAEL) of dihydrocapsiate was 1000 mg/kg/day for both sexes in this 26-week gavage study.
Natural Occurrence and Physiological Properties
Capsinoids are novel capsaicin analogues isolated from the fruit of the nonpungent chili pepper cultivar, CH-19 Sweet. 1 Kobata et al 2, 3 determined the structures of capsinoids and named capsiate (4-hydroxy-3-methoxybenzyl (E)-8-methyl-6-nonanoate; Figure 1 ), dihydrocapsiate (4-hydroxy-3-methoxy-benzyl 8-methylnonanoate, DHC; Figure 2 ), and nordihydrocapsiate (4-hydroxy-3-methoxybenzyl 7-methyloctanoate; Figure 3 ), respectively. Capsinoids have an ester bond instead of the amide bond between the vanillyl moiety and fatty acid chain normally found in capsaicin.
Capsaicin ([E]-[4-hydroxy-3-methoxybenzyl]-8-methyl-6nonenamide; Figure 4 ) is well known to have a variety of desired physiological effects. However, the strong, pungent nature of capsaicin limits the quantities of this compound that can be employed in food and medicine. In contrast, capsinoids are nonpungent, making it possible to use capsinoids in food applications without the attendant heat effect found in capsaicin. Although capsinoids occur naturally in various capsicum pepper cultivars, with the exception of CH-19 Sweet, the quantity of capsinoids is small compared to that of capsaicinoids in capsicum cultivars. 1 Kobata et al 4 reported enzymatic synthesis of capsinoids with vanillyl alcohol and fatty acid. Using these methods, Ajinomoto Co., Inc. recently developed the process for producing dihydrocapsiate (DHC), thereby increasing its availability. Dihydrocapsiate could provide an alternative source of capsinoids for use as a food ingredient. plasma urea nitrogen, glucose, phospholipids, triglycerides, total cholesterol, free fatty acids, glutamic pyruvic transaminase, and alkaline phosphatase, and a slight hyperemia (without hemorrhage) in the liver. Akagi et al 6 conducted a dietary feeding study administering capsaicinoids 0%, 0.0625%, 0.125%, 0.25%, 0.5%, and 1.0% (approximately 0, 94, 188, 375, 750, and 1500 mg/kg BW, respectively) to B6C3F 1 mice for 13 weeks. Mice, especially female mice, in all capsaicinoidtreated groups showed reduced body weight gain. The liver/ body weight ratios in both sexes were increased by capsaicinoid administration, whereas the kidney:body weight ratios of capsaicinoid-treated groups were slightly decreased. Renal lesions were identified histologically as tubular dilatation of the kidneys, and these lesions were observed in all male mice receiving the highest dose (1%), but not in males at lower doses or in females at any dose.
Capsinoid Safety
Recently, a series of studies has been published dealing with the safety of capsinoids. These have included studies of acute toxicity, 7 26-week chronic toxicity, 8 2-generation reproductive toxicity, 9 and teratology in rats and rabbits. 10 A study in humans evaluating safety and pharmacokinetics was also published. 11 Kodama et al 8 published a chronic toxicity study in which rats were administered CH-19 Sweet extract (containing approximately 7.5% capsinoids) to rats. In that study, Sprague-Dawley rats received CH-19 Sweet extract by gavage for 26 weeks at dose levels of 0 (vehicle), 1.25, 2.5, and 5.0 ml/ kg/day (equivalent to approximately 90, 180, and 360 mg/kg capsinoids, respectively). These doses equated to 18, 36, and 72 mg/kg/day DHC, respectively. The effects observed (only in male rats at the highest dose administered) included increased numbers of plasma-derived segmented neutrophils and slight increases in plasma levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH). Male liver weights were also increased and histopathological examination revealed increases in the incidence and severity of focal necrosis in hepatocytes. The no observable adverse effect level (NOAEL) of capsinoids was estimated to be approximately 180 mg/kg/day in males and 360 mg/kg/day in females, respectively.
DHC Safety
The safety of DHC was recently evaluated in a systematic manner. A series of studies investigating the compound's potential for genotoxicity, 12 acute toxicity, 13 subchronic toxicity, 14, 15 and teratology in rats and rabbits 16 were published in the International Journal of Toxicology. Kodama et al performed a 13- week gavage toxicity study in Sprague-Dawley rats (10/ sex/group). 14 The rats received DHC at dose levels of 0 (vehicle), 100, 300, or 1000 mg/kg/day and were observed for antimortem and postmortem signs of toxicity, including changes in clinical signs, body weight, food consumption, water intake, ophthalmology, clinical pathology (clinical chemistry, hematology, urinalysis), tissue findings (macroscopic and microscopic examination), as well as organ weights. Changes were observed in the high-dose rats only and included slightly increased ALT activity in males; increased calcium, percentage of albumin fraction and A/G (albumin/globulin) ratio in females and increased total protein in both males and females. The percentage of g-globulin fraction decreased in high-dose female rats. Liver weights increased in the high-dose rats of both sexes. No changes in histopathology attributable to the test article were observed, suggesting that the changes observed in blood chemistry and liver weights were adaptive and not toxicological in nature. The authors concluded that the NOAEL of DHC was 1000 mg/kg/day for both male and female rats in that 13-week gavage study.
Watanabe et al 15 reported the results of a 13-week gavage toxicity study of commercial-grade DHC in Sprague-Dawley rats (10/sex/group). The rats received DHC at dose levels of 0 (vehicle), 100, 300, or 1000 mg/kg/day and were observed for antimortem and postmortem signs of toxicity, including changes in clinical signs, body weight, food consumption, water intake, ophthalmology, clinical pathology (clinical 
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International Journal of Toxicology 29(2S) chemistry, hematology, urinalysis), tissue findings (macroscopic and microscopic examination), as well as organ weights. A single change, slightly increased liver organ weights in high-dose males (1000 mg/kg/day), was attributable to the test article. Infrequent and minimal liver changes that failed to achieve statistical significance were also reported. In the absence of chronic study or recovery group data, 300 mg/kg/ day for male rats and 1000 mg/kg/day for female rats were conservatively designated as the no observable adverse effect level (NOAEL) of DHC in this 13-week gavage study. The purpose of performing this 26- week study was to obtain chronic toxicity data in rats and evaluate the potential for any adverse effects observed to ameliorate during a 4-week recovery period.
Materials and Methods

Animals and Animal Husbandry
Male and female Sprague-Dawley SPF rats (Crl:CD(SD) Atsugi Breeding Center, Charles River Japan, Inc., Kanagawa, Japan) were acclimated to laboratory conditions during 9-and 10-day quarantine periods for males and females, respectively. During this time, the rats were observed daily, weighed, and subjected to a pretreatment ophthalmologic examination. Rats accepted for use in the study were randomized using stratification by weight into 4 groups of 20 rats/sex as the main groups, and 10 rats/sex for the control and the high-dose recovery groups. Individual body weight on the first day of test article (TA) administration was in the range of 209-249 g and 142-198 g for males and females, respectively. Rats were housed in an animal room where the temperature was maintained at 23 C + 3 C, the relative humidity was 50% + 20%, the air ventilation was 10 to 15 changes per hour, and the room was illuminated for 12 hours a day (7:00 AM to 7:00 PM). Rats were individually housed in bracket-type metallic wire-mesh cages (W 254 Â D 350 Â H 170 mm: Lead Engineering Co., Ltd., Tokyo, Japan). The rats were allowed free access to pelleted diet CRF-1 (radiation-sterilized, Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water.
The TA, Dose Preparation, and Reversibility
The TA, DHC, was a viscous, colorless to yellow liquid. The test material, supplied by Ajinomoto Co., Inc. (Tokyo, Japan; lot no. 070813), was 95.4% pure and contained 8-methylenonanoic acid, the acyl residue of DHC (3.9%). The TA was stored at À1 C to 8 C throughout the study to protect it from heat and light.
The vehicle, medium-chain triglyceride (MCT, product name Actor M-2), was manufactured by Riken Vitamin Co., Ltd. (Tokyo, Japan).
Based on toxicity study guidelines (MHLW 1996), a high top dose (1000 mg/kg/day) was chosen for the high-dose level, and 2 additional dose levels (at one-half log intervals [300 and 100 mg/kg/day]) and a vehicle control were chosen to complement the high dose. The oral route of administration was chosen, as it is the intended human exposure route. The TA was diluted in the vehicle and administered by gavage once daily to rats for 26 weeks at a volume of 5 mL/kg body weight using flexible stomach tubes. Rats in the control group received the vehicle alone. Following the final dose, rats in the recovery groups were maintained without TA administration for a 4-week period.
Antemortem Evaluative Parameters
During the dosing period, rats were observed daily, before and after dosing, for the presence of clinical signs. During the recovery period, rats were observed once a day in the morning. All animals were weighed 3 times during administration week 1 (ie, days 1, 4, and 7), twice weekly for weeks 2-13 (ie, every 3 or 4 days), once weekly for weeks 14-28 (ie, every 7 days, twice a week for recovery week 1 (ie, recovery days 1 and 7), and once weekly every 7 days thereafter. On the day of necropsy, rats were fasted for approximately 16 hours and weighed prior to sacrifice.
Food consumption and water intake were measured for the day ending with the first TA administration. Thereafter, the individual rat's daily food consumption was calculated based upon the first 6 days' cumulative food consumption and weekly cumulative food consumption thereafter. Each rat's daily water consumption was calculated for day 1 (same as food) and days 1-4 of administration, and once per week thereafter.
Ophthalmologic examinations were performed prior to TA administration (day 4 of the quarantine/acclimation period), during administration week 13 (day 83 or 84) and week 26 (day 177 or 178), and in week 4 of recovery (recovery day 23 or 24). During both the dosing and recovery periods, the first 6 male and 6 female rats from each group (animal nos. 01 to 06 in the last 2 digits for the low-and middle-dose groups, and 21 to 26 in the last 2 digits for the control and high-dose groups) were subjected to macroscopic observation of the anterior portion, intermediate optic media and fundus oculi using a direct ophthalmoscope (BXa-13 model: Neitz Instruments Co., Ltd., Tokyo, Japan). Before the examination, a mydriatic agent (Mydrin P, Santen Pharmaceutical Co., Ltd., Osaka, Japan) was applied to the eye.
Rats were fasted overnight (16-20 hours) prior to the scheduled necropsy (the next day after the end of the dosing and recovery periods). Rats were anesthetized with ether, and blood samples were obtained from the abdominal aorta into blood-collecting tubes. For hematological evaluation, blood was collected into 2 types of tubes; the first containing EDTA-2K (SB-41: Sysmex Corporation, Hyogo, Japan) and the second containing 3.8% sodium citrate (1 volume to 9 volumes of blood). The blood samples were centrifuged at approximately 1600 Â g for 10 minutes, and the plasma was collected. The hematological parameters and the analytical methods employed to determine them are listed in Table 1 . May-Gruenwald-Giemsa stained blood smear specimens were prepared for all rats to be held in reserve in case microscopic evaluation was needed.
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For the evaluation of changes in blood chemistry, blood samples were collected into 2 test tubes, 1 containing the coagulation promoting agent, Venoject II-Autosep (Terumo Corporation, Tokyo, Japan), and the other containing heparin (approximately 20 units of heparin per 1 mL blood). The parameters measured and methods employed for blood chemistry indices are listed in Table 2 .
Urinalyses were performed during administration weeks 13 (day 85 or 86), and 26 (day 176 or 177), and in recovery week 4 (day 22 or 23). All animals were individually placed in cages equipped with a urine collector, and 4-hour urine specimens were collected. During these periods, the rats were deprived of food but allowed free access to water. Thereafter, 20-hour urine samples were obtained, during which time the rats were permitted free access to both food and water. The urinary parameters evaluated in this study are listed in Table 3 , as are the methods by which they were analyzed.
Postmortem Evaluative Parameters
All surviving rats were fasted overnight, weighed, and anesthetized with ether. After collection of blood samples, each animal was exsanguinated and subjected to necropsy. Tissues were observed for grossly observable abnormalities. Organ weights of the brain (cerebrum and cerebellum), pituitary, thyroids (and parathyroids), adrenals, thymus, spleen, heart, lungs (including bronchial tubes), salivary glands (sublingual and submandibular), liver, kidneys, testes/ovaries, uterus, prostate, and seminal vesicles were obtained. For bilateral organs (ie, thyroid [and parathyroid], adrenals, lungs [including bronchial tubes], salivary glands [sublingual and submandibular], kidneys, testes/ ovaries, and seminal vesicles), organ weight was obtained unilaterally; however, evaluation was performed on the sum total of values of the right and left organs. Blood for hematology and clinical chemistry evaluations was collected from rats sacrificed in a moribund condition. Moribund rats underwent necropsy and histopathology examinations, but the organs were not weighed.
In addition to the preceding list of organs that were weighed, other organs or tissues retained for histologic examination for the nonrecovery groups included: spinal cord (thoracic), sciatic nerve, eyeball, optic nerve, Harderian gland, submandibular lymph node, mesenteric lymph node, thoracic aorta, trachea, tongue, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, pancreas, urinary bladder, epididymis, oviduct, vagina, mammary gland (inguinal region), sternum (including bone marrow), femur (including bone marrow), femoral skeletal muscle, skin (inguinal region), macroscopic lesions, nasal cavity, and Zymbal's gland. The larynx and the site of animal identification (ear auricle) were removed and preserved, but not examined histologically. In addition to the preceding list of organs, other organs or tissues retained for histologic examination for the recovery groups were the stomach, pancreas, mammary glands (only for females), and subcutaneous nodules. Most organs/tissues were fixed and preserved in phosphate-buffered 10 vol% formalin. The eyeballs and optic nerve were fixed initially in phosphate-buffered 3 w/v% glutaraldehyde/2.5 vol% formalin and the testes and epididymides in Bouin's solution. Subsequently, these organs/tissues were preserved in phosphate-buffered 10 vol% formalin. All the organs/tissues to be examined were embedded in paraffin, sectioned, and stained with hematoxylin/eosin. Organs/tissues of all control and high-dose group rats (both sexes) were examined microscopically. For the heart, both vertical sections 
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International Journal of Toxicology 29(2S) (containing the apex side of the left and right ventricles) and cross sections were examined. Liver sections (both sexes) and kidney sections (females) from the mid-and low-dose groups were examined based on the findings in the high-dose rats.
Statistical Analysis of Data
Quantitative data (ie, body weight, body weight gain, food consumption, water intake, urinalysis, hematology, blood chemistry, and organ weight) were analyzed as follows. Total cholesterol (T. cho) CEH-COD-POD method (a) (7) Triglyceride (TG) LPL-GK-GPO-POD method (a) (8) Phospholipids (PL) PLD-ChOD-POD method (a) (9) Total bilirubin (T. bilirubin) Bilirubin oxidase method (a) (10) Glucose Glucose dehydrogenase method (a) (11) Blood urea nitrogen (BUN) Urease-LEDH method (a) (12) Creatinine Creatininase-creatinase-sarcosine-oxidase-POD method (a) (13) Sodium (Na) Ion selective electrode method (a) (14) Potassium (K) Ion selective electrode method (a) (15) Chloride (Cl) Ion selective electrode method (a) (16) Calcium (Ca) OCPC method (a) (17) Inorganic phosphorus (P) Molybdic acid method (a) (18) Total protein (TP) Biuret method (a) (19) A/G ratio Calculated from protein fractions - (20) Protein fractions Electrophoresis using a cellulose acetate membrane (b) Data obtained during/at the end of the dosing period were analyzed for homogeneity of variance using Bartlett's test with the levels of significance set at 1% for 2-tailed testing. 17 Homogeneous data were assessed using Dunnett's test to compare the mean values between the control group and each dose group with the levels of significance set at 5% and 1% for 2-tailed testing. 18 Heterogeneous data were assessed using Steel's test, with the levels of significance fixed at 5% and 1% for 2-tailed testing. 19 Data obtained during/at the end of the recovery period were analyzed for homogeneity of variance using F tests, with the levels of significance set at 5%. Homogeneous data were assessed using Student's t test to compare the mean values between the control group and high-dose group, with the levels of significance set at 5% and 1% for 2-tailed testing. Heterogeneous data were assessed using the Aspin-Welch t test, with the levels of significance fixed at 5% and 1% for 2-tailed testing. All analyses were performed using the integrated statistical package, SAS version 8.2 (SAS Institute, Cary, NC).
The histopathological findings in liver (both sexes) and kidney (females), which were examined in the low-and mid-dose groups because of findings in the high-dose rats, were statistically assessed using Fisher's exact test, with the level of significance fixed at 5%. 20 
Results
No rats died during the course of the study (in neither the dosing nor the recovery periods); one high-dose male (1000 mg/kg) was sacrificed in a moribund condition (animal showed prone/ lateral position and bradypnea) on day 127. During the dosing period, subcutaneous masses of the neck or axillary region were observed in 2 high-dose females. One of these females was sacrificed at the end of the dosing period; in the other, the subcutaneous masses (neck) were also observed during the recovery period. The other rats appeared normal throughout the study.
Mean body weight was unaffected during both the 26-week dosing period and the 4-week recovery period (Table 4A and  4B) . Likewise, there were no statistically significant differences in mean body weight gains during the 26-week dosing period (Table 4C ). Body weight gain was statistically higher in high-dose females compared to the control group on the last day (day 28) of the recovery period (Table 4D , p .05). This occurred due to the lack of weight gain in the controls.
Food consumption was higher in high-dose females compared to the control group from administration day 77 (Table 5A , p .01) through the end of the recovery period (Table 5B , p .01). All other female groups (ie, low-and mid-dosed) and all the male groups had food consumption comparable to their respective controls.
Water consumption was higher in the high-dose (1000 mg/ kg/day) groups, although statistical significance was achieved only in females and only on days 25 and 144 (Table 6A ; p .05). Water consumption remained higher in high-dose females during the recovery period; statistical significance was achieved only on recovery day 28 (Table 6B ; p .05). The water consumption of all other groups was comparable to the controls.
The results of hematology analyses are presented in Tables  7A and 7B . High-dose group (1000 mg/kg/day) mean differences that achieved statistical significance at the end of the TA administration included increased platelet count (p .05), decreased neutrophil ratio (p .05) in males, an increase in mean corpuscular volume (MCV, p .05) and a decrease in red blood cells (RBC, p 0.05) in females (Table 7A ). Mid-dose (300 mg/kg/day) findings that achieved statistical significance at the end of the administration period included decreased fibrinogen (Table 7A , p .05; both sexes). Lowdose (100 mg/kg/day) findings that achieved statistical significance at the end of the administration period included increased number of eosinophils in females (p .05). The only statistically significant change observed at the end of the administration period that continued until the end of the recovery period was an increased platelet count (p .05) observed in high-dose (1000 mg/kg) males (Table 7B) . No abnormalities were observed in females during the recovery phase (Table 7B ).
The results of blood chemistry analyses obtained at the end of dosing are presented in Table 8A . High-dose group parameters that achieved statistically significant increases when compared to their respective controls included: ALT (both sexes, p .01), total protein (males, p .01; females, p .05), calcium (males, p .05; females, p .01), phospholipids (males only, p .01), total cholesterol (males only, p .01), and a 2 -globulin fraction (males only, p .05). Statistically significant decreases observed in high-dose females only included g-globulin fraction (p .05) and creatinine (p .05). At the middle dose, several blood chemistry parameters achieved statistically significant increases in males at dosing termination. These parameters included: ALT activity (p .05), phospholipids (p .05), and a 2 -globulin fraction (p .01). Blood chemistry comparisons at the end of the recovery period identified 2 parameters in high-dose rats that achieved statisticalsignificance: a decrease in b-globulin fraction (males, p .01; females, p .05), and an increase in a 1 -globulin fraction in males (Table 8B , p .01).
A summary of the urinalysis (at the end of dosing and recovery period) results is presented in Tables 9A, 9B, 10A and 10B. At week 26 of administration, a tendency toward decreased numbers of positive reactions for ketone bodies was observed in both sexes in the high dose (1000 mg/kg) group; this was the result of vehicle metabolism. Statistically significant increases in urine volume (p .05), and sodium, potassium and chloride excretion (p .01) were observed in high-dose males at the termination of dosing. There were no differences observed in males during the recovery period. The reverse was observed in females (ie, statistically significant increases in urine volume, sodium, potassium, and chloride excretion in the recovery period, but no differences during the dosing period). Based on the above results and in the absence of similar alterations in serum electrolytes, these changes were designated as random.
32S
International Journal of Toxicology 29(2S) Day   Dose  1  4  7  11  14  18  21  25  28  32  35  39  42  46  49  53  56  60  63  67  70   Males  0  mg/kg   Mean 229 253 282 313 337 364 383 408 422 443 457 473 486 500 508 522 528 539 545 557 565  SD  9  11  12  16  19  24  26  29  31  33  34  35  35  37  36  37  39  41  41  43  45  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  100  mg/kg   Mean 230 254 284 318 341 369 389 412 428 449 464 482 496 511 519 534 539 552 558 567 574  SD  9  12  14  20  23  26  30  32  33  35  36  38  40  40  42  44  45  46  45  45  47  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20 SD  10  12  14  17  19  23  26  25  25  26  28  28  30  32  31  31  30  32  32  33  34  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  300  mg/kg   Mean 170 179 190 201 212 226 233 244 250 260 266 274 281 286 289 297 301 305 308 311 314  SD  11  13  13  16  16  18  23  25  26  29  32  32  34  37  36  38  40  42  41  42  43  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  1000  mg/kg   Mean 171 182 194 208 220 233 239 249 253 261 269 276 281 287 291 298 299 305 308 312 315  SD  15  12  13  14  15  17  18  20  21  22  22  23  23  24  25  25  25  25  27  27  26  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30   Day   Dose  74  77  81  84  88  91  98  105 112 119 126 133 140 147 154 161 168 175 182   Males  0  mg/kg   Mean 575 580 589 592 602 606 618 630 641 651 660 668 679 686 695 703 710 718 725  SD  46  47  48  47  49  50  49  51  52  52  52  53  53  53  53  54  54  56  57  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  100  mg/kg   Mean 584 589 599 603 615 618 632 643 655 665 675 682 691 700 709 716 723 732 739  SD  46  49  49  50  50  50  53  56  57  58  61  62  64  66  66  68  67  71  71  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  300  mg/kg   Mean 572 576 584 590 600 604 617 627 637 648 655 665 672 678 689 696 704 710 714  SD  62  63  64  65  67  68  70  71  73  76  74  79  79  79  80  84  83  83  82  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20 SD  34  33  34  36  35  37  37  37  39  41  40  41  42  42  44  45  45  47  46  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  300  mg/kg   Mean 318 321 326 329 332 333 340 346 352 355 360 365 369 375 379 381 387 390 394  SD  43  45  45  44  45  48  54  54  55  56  57  61  63  63  67  66  69  68  70  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  1000  mg/kg   Mean 319 322 327 330 332 332 340 344 349 354 360 364 371 375 380 383 388 393 397  SD  27  27  28  29  29  29  29  30  32  32  34  33  36  35  37  38  39  41  42  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30 a Data expressed as mean and standard deviation (SD); n ¼ no. of observations. No significant differences were observed when comparing treated and control groups.
Ophthalmological examinations at the end of dosing were unaffected by the administration of TA (Table 11 ).
The results of absolute and relative organ weight (to body weight) analyses performed at the end of dosing are summarized in Tables 12 and 13 , respectively. Statistically significant increases in the absolute and relative weight of the liver were observed in both sexes in the high-dose (1000 mg/kg) group. Additional statistically significant changes observed included: higher values in the kidney (relative weight for males, absolute weight for females), heart (relative weight for males, absolute weight for females), spleen (relative weight for males), salivary glands (relative weight for males, absolute weight for females), pituitary (absolute weight for females) and lung (absolute weight for females) in the highdose (1000 mg/kg) group, and pituitary (absolute weight for females) in the 300 mg/kg group. At the end of recovery, statistically significant higher values in the absolute and relative weight in the pituitary were observed in females in the highdose (1000 mg/kg) group. Additional statistically significant changes observed included: higher values in salivary glands (absolute weight for females), adrenal (absolute weight for females), and liver (relative weight for females) in the highdose (1000 mg/kg) group (Tables 14 and 15 ).
Necropsy findings are summarized in Tables 16A and 16B . A cerebral nodule was observed in 1 high-dose male that had been sacrificed in a moribund state. Other grossly observable lesions were judged to be incidental based on their rare occurrence and the absence of histopathology correlates. At the termination of dosing and at the end of the recovery period, there were no test article-related changes in any animal.
Microscopic changes observed at the termination of dosing are summarized in Table 17A . Oligodendroglioma was observed in the single rat that had been sacrificed moribund (high-dose male); it corresponded to the nodule observed at necropsy. A small number of high-dose rats showed minimal changes (not statistically significant) in the liver. Statistically significant increases in both the incidence of kidney tubule regeneration and kidney urinary cyst hyaline were observed in high-dose females (1000 mg/kg) at the termination of dosing. At the end of recovery, 2 adenocarcinomas and increased incidence of mammary gland focal or lobular hyperplasia were observed in high-dose females (Table 17B ; 1000 mg/kg). These findings and other observations were judged to be incidental or spontaneous for this strain of rat.
Discussion
In this study, as in 2 previously reported studies, 14, 15 there were no test article-related effects on mortality, body weights, body weight gain, or ophthalmology. At necropsy, the high-dose male rat sacrificed in a moribund condition (Day 127) was found to have a nodule in the cerebrum, which was diagnosed as an oligodendroglioma during histopathology. This lesion was the cause of its morbidity and judged to be unrelated to treatment based on historical incidence. 21, 22 Food consumption was statistically increased in high-dose females (not males) compared to controls late in the administration period and during the recovery period. This finding was consistent with statistically significant increases in body weight gain in high-dose females (not males) on the last day (day 28) of the recovery period. The difference in body weight gain was thought to be related to differences in food consumption between the 2 groups and have no biological meaning given the small quantitative difference and the lack of an effect on body weights. In the 2 previously reported 13-week 
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International Journal of Toxicology 29(2S) Day   Dose  4  7  11  14  18  21  25  28  32  35  39  42  46  49  53  56  60  63  67  70   Males  0  mg/kg   Mean 24  52  84 107 134 154 178 192 214 227 243 257 270 278 292 299 310 316 328 335  SD  4  6  10  14  18  20  24  25  28  29  30  31  32  31  33  34  36  37  39  40  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  100  mg/kg   Mean 25  54  88 112 139 159 183 198 220 234 252 266 282 290 305 310 322 328 337 344  SD  6  8  14  18  21  25  28  28  30  32  34  35  35  37  39  40  41  40  39  42  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20 SD  5  7  9  11  15  19  17  18  18  21  21  23  24  24  23  23  25  25  26  26  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  300  mg/kg   Mean  9  20  31  42  56  63  74  80  90  96 103 111 116 119 126 131 135 138 141 144  SD  6  10  11  12  13  16  18  19  23  26  26  28  30  29  32  33  35  34  35  37  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  1000  mg/kg   Mean 11  23  36  48  61  68  78  82  90  98 104 110 115 120 126 128 134 137 141 144  SD  8  8  9  11  12  13  14  16  17  17  18  19  19  20  20  20  20  23  23  23  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30   Day   Dose  74  77  81  84  88  91  98  105 112 119 126 133 140 147 154 161 168 175 182   Males  0  mg/kg   Mean  346 351 360 363 373 377 388 401 411 422 431 439 450 457 465 473 481 489 495  SD  42  43  43  43  45  45  45  46  47  48  47  49  48  49  49  50  50  52  53  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  100  mg/kg   Mean  354 359 369 374 385 388 402 413 425 435 446 452 462 470 479 486 494 502 510  SD  41  43  44  44  45  45  48  50  51  52  56  56  59  60  61  62  61  65  65  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  300  mg/kg   Mean  343 348 356 362 372 375 388 399 409 419 426 437 444 450 460 468 476 482 486  SD  55  56  57  58  60  61  63  64  66  69  68  72  72  73  74  77  77  77  76  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  1000  mg/kg   Mean  332 337 346 351 360 363 376 383 394 404 415 425 433 440 449 456 463 468 472  SD  53  54  56  57  59  59  60  62  64  66  67  71  71  71  73  75  76  78  80  n  30  30  30  30  30  30  30  30  30  30  30  29  29  29  29  29  29  29  29  Females  0  mg/kg   Mean  138 138 143 144 147 150 156 161 164 170 175 178 182 187 193 194 198 204 206  SD  22  21  23  24  23  24  24  25  25  26  27  27  28  30  33  34  34  35  36  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  100  mg/kg   Mean  148 148 153 158 161 163 169 171 175 182 186 191 196 200 205 207 211 217 219  SD  27  25  25  28  27  29  29  29  31  33  32  33  34  35  36  38  38  40  40  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  300  mg/kg   Mean  148 151 156 159 161 163 170 176 182 185 190 195 199 205 208 211 217 220 224  SD  36  38  38  37  38  41  47  48  48  50  51  54  57  57  61  60  63  62  64  n  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  20  1000  mg/kg   Mean  148 150 156 159 160 161 169 172 178 183 189 193 200 204 209 212 217 222 226  SD  23  24  25  25  25  27  27  29  30  31  32  32  34  34  36  37  38  40  41  n  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30  30 a Data expressed as mean and standard deviation (SD); n ¼ no. of observations. No significant differences were observed when comparing treated and control groups. Mean 25 25 26 26 26 26 26 26 26 25 25 24   24 24 23 23 23 23   24   23   23   22   23 22   22   22 22   SD  2 2 2 3 3 3 3 3 3 3 3 2   3 3 2 3   3   3   3   3   3 studies, 14,15 no effect on female (or male) food consumption was observed in one study, whereas increased male (but not female) food consumption was observed in the other. 15 These variations are within the normal range of biological variation for the performing laboratory.
Water consumption was higher in the high-dose rats, although it rarely achieved statistical significance and then only in the females. Statistically increased urine volume and increased urine Na, K, and Cl in high-dose males (not females) were also found. In the absence of functional or histopathological abnormalities of the kidney or changes in serum electrolyte levels, these findings were judged to have no toxicological significance. These findings and conclusions were similar to those that have been reported previously. Kodama et al 14 reported no effects on either water consumption or urine volume or constituents. Watanabe et al 15 noted infrequent statistically significant increases in water consumption, urine volume, and constituents in high-dose males, not females; again in the absence of functional or structural renal abnormalities.
The decreased number of animals showing positive reactions for ketone bodies observed in the high-dose (1000 mg/ kg) group was a reflection of the increased metabolism of the lipid vehicle (medium-chain triglyceride) administered to the control group, which received a higher dose of vehicle than treated rats and was not toxicological in nature.
Hematological examination revealed a statistically increased platelet count in high-dose (1000 mg/kg) male rats only. No alterations in related parameters such as prothrombin time, activated partial thromboplastin time or fibrinogen were observed, and histopathological examination revealed neither inflammatory changes nor abnormalities in the hematopoietic organs. The statistical, but quantitatively minimal, increase in platelet counts was not considered adverse because it remained within the normal historical control range for the performing laboratory. The statistically significant decrease in neutrophil percentage (but not absolute number) in high-dose males, but not females, was not biologically meaningful, as it remained within the historical control range for the performing laboratory and was caused by a slightly higher than normal control value for this strain of rat. The statistically significant decrease of fibrinogen values in mid-dose rats (p .05; both sexes) was judged to be an incidental change since it was not dose related. The other 2 high-dose statistical findings (ie, decreased RBC and increased MCV in the females), were not biologically significant since the values were found to be within the normal control values for the performing laboratory; the observation was made in 1 sex only, and the 2 previously reported studies 14, 15 failed to make the same observation.
Blood chemistry examination revealed statistically significant increased ALT activity in mid-dose males (300 mg/kg/day) and high-dose (1000 mg/kg/day) males and females; increased phospholipids in mid-and high-dose males; and increased total cholesterol in high-dose males. The increased ALT activity and the increase in total cholesterol might have been related to DHC administration, as they were also observed in both previously reported studies. 14, 15 However, these increases were considered to have no toxicological significance since they remained within the range of the historical control at the performing laboratory; there were no changes in AST or LDH activities (in this study or the 2 previously published studies), and the histopathological examination revealed no findings indicating abnormalities of the liver or kidney. Blood chemistry evaluation also revealed statistical increases in total protein in high-dose rats (both sexes), increased a 2 -globulin fraction in high-and mid-dose males, and decreased g-globulin fraction in high-dose females. These findings were judged to have no toxicological significance since all values remained within the historical control range for the performing laboratory; the changes were minimal, there were no changes in other fractions, and decreased total protein was not observed. The increase of calcium in the high-dose rats was judged to be a statistical phenomenon and not one of biological importance because of the extremely small quantitative difference between the treated and high-dose groups. No biological meaning was ascribed to the decrease of creatinine in the high-dose female rats.
There were no histopathology observations indicative of abnormal changes related to the administration of the TA. A small number of rats (not statistically significant) showed minimal liver changes. Other studies reported liver changes; however, the changes were infrequent (not statistically significant), histologically minimal, and considered within the normal range. 18 Although ALT was slightly elevated, it was within the normal range and the other liver enzymes (AST, LDH, ALP) were unaltered.
Similar observations that did not achieve statistical significance were reported by Watanabe, 15 but not by Kodama; 14 both previous studies employed the same dose levels as the current study. These observations were not toxicological in nature based on the following facts: (1) the low frequency of the finding (not statistically significant); (2) the lack of severity of the finding (minimum) and the fact that the finding was never observed in a more severe state; (3) the absence of increased quantitative or qualitative findings associated with increasing length of exposure (TA administration from 13 to 26 weeks); (4) the complete absence of histopathology differences following a 4-week recovery period; and (5) the frequency and minimal nature of the observations were considered within the normal range of findings for the rat. In the previously reported 13-week study, in spite of the absence of statistical significance, Watanabe 15 decided to be conservative and not to define the NOAEL as 1000 mg/kg/day because of the absence of both long-termexposure data and a recovery period. The current study, as it provided both chronic and recovery data, resolved that issue. As a final check, the observations reported in Watanabe 15 (statistically nonsignificant, infrequent, and minimal liver observations) were compared to those observed in this 26-week study and determined to be qualitatively and quantitatively indistinguishable from the range of findings observed in the control rats.
The statistically significant increase in the frequency of minimal kidney tubule regeneration and urinary cyst hyaline were observed in high-dose females. The cyst and hyaline kidney changes most likely represented aging nephropathy. 23 These changes were judged to be incidental because the incidence was within the normal spontaneous rate observed at the performing laboratory.
Other histopathology and organ weight findings lacked toxicological importance owing to lack of consistency (absolute and relative weights) of the finding, the absence of abnormal histopathology findings in any of the organs and the failure to replicate the finding by either Kodama 14 or Watanabe. 15 At the end of the 4-week recovery, slight differences in the incidences of mammary histopathology findings and pituitary weights were noted. In the Sprague-Dawley SPF rats (Crl: CD(SD)) used for this study, age-related, pituitary hormone dependent, spontaneous proliferative changes of the mammary glands were well-known. Data observed therein were consistent with that knowledge. Of the 12 rats observed to have proliferative changes in the mammary gland (3 males and 9 females, 4 controls and 8 high-dose), 10/12 had pituitary weights that exceeded their respective group means. Inasmuch as: (1) the incidences of the mammary changes observed in treated rats did not differ from that observed in the controls;
(2) there were no treatment-related changes in the histopathological findings of the pituitary; and (3) these changes were not replicated in either of the previous studies, this finding was not considered to be of toxicological importance.
The findings in the current study were comparable to those described by Kodama 14 and Watanabe 15 in their 13-week studies; all 3 studies employed the same dose levels (0, 100, 300, and 1000 mg/kg/day). The liver findings, limited to the high dose, included (1) higher ALT activity (in treated males and females in both studies), which achieved statistical significance only in males and only in the Watanabe study 15 ; (2) increased absolute and relative liver weights in the high-dose rats (both sexes); and (3) an increased incidence in the frequency of minimal liver changes in males, which was reported, but did not achieve statistical significance in Watanabe (2008c) 15 and was not reported in Kodama (2008c) . 14 Based on the new data generated in this study and a comparison of the hypertrophic slides in the Watanabe study, 15 it is clear that the NOAEL for all 3 of these gavage rat studies is 1000 mg/kg/day for a period of up to 6 months.
The absence of toxicity following 13 weeks and 26 weeks of gavage administration of DHC in rats was consistent with the findings reflected in the entire database now available on this food ingredient. Genotoxicity for DHC, as evaluated in the bacterial reverse-mutation test, chromosomal aberration test, micronucleus test, gene mutation assay with transgenic rats, and the single-cell gel assay, was shown to be low or extremely low. 12, 13 Low acute toxicity (LD50 > 5000 mg/kg) 13 and teratological potential in both the rat and rabbit were shown to be quite low (NOAEL ¼ 1000 mg/kg/day). 16 Studies investigating the metabolism and/or pharmacokinetics of DHC demonstrated the rapid and complete metabolism and elimination of DHC and the formation of a series of metabolites prior to DHC reaching the systemic circulation. 24, 25, 26 There now appear to be sufficient data available to suggest that the order of potential toxicity in animals of these structurally related compounds is: capsaicin or a crude aqueous extract of Capsicum annuum L. > CH-19 Sweet extract > DHC. The toxicity of CH-19 Sweet extract is clearly higher than that found for DHC. CH-19 Sweet extract (expressed as capsinoids) is nongenotoxic in Salmonella typhimurium and Escherichia coli; no deaths result from a single acute administration of 1425 mg/kg (the highest dose tested by Watanabe 7 ) ; no toxicity is observed in a 2-generation reproduction study in rats at a dose of approximately 350 mg/kg (the highest dose tested in Kodama 9 ); no teratogenic effects are observed in rats or rabbits at approximately 361 and 75 mg/kg/day, respectively (the highest doses tested, Bernard 16 ); and a 26-week gavage study in rats shows hepatic toxicity (ie, focal necrosis) at approximately 360 mg/kg/day. 8 Capsaicin (or the crude aqueous extract of Capsicum annuum L) appears to have a higher toxicity potential than CH-19 Sweet extract. Rats receiving gavage doses of capsaicin (50 mg/kg) or crude aqueous extract of Capsicum annuum L. (500 mg/kg) for 60 days exhibit statistically significant reductions of body weight, plasma urea nitrogen, glucose, phospholipids, triglycerides, total cholesterol, free fatty acids, glutamic pyruvic transaminase, and alkaline phosphatase, and a slight hyperemia (without hemorrhage) in the livers. 5 Similarly, in a 13-week dietary feeding study, 6 mice were administered approximately 0, 94, 188, 375, 750, and 1500 mg/kg. Mice in all capsaicinoid-treated groups, particularly female mice, show reduced body weight gain, increased liver/body weight ratios (both sexes), and decreased kidney/body weight ratios. Renal lesions (tubular dilatation) were observed in all male mice receiving the highest dose (1500 mg/kg).
Conclusions
This study, involving the daily gavage administration of DHC to rats for 26 weeks at doses of 0 (vehicle), 100, 300, or 1000 mg/kg/day, demonstrates the absence of toxicological effects up to and including the highest dose tested. There are also no toxicological observations within the 4-week recovery period. Based on the results of this study, the 26-week gavage no observable adverse effect level (NOAEL) for DHC is 1000 mg/kg/day for both male and female rats. 
